Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
inupadenant · 2 trials · 3 indications
Incidence of dose-limiting toxicities
Incidence of adverse events (AEs), serious adverse events, AEs leading to discontinuation, deaths, and clinically significant laboratory abnormalities.
Time from first dose to the date of first documented radiologic progression per RECIST v1.1 or time of death, whichever comes first
Incidence of adverse events (AEs), serious adverse events (SAEs), DLTs, AEs leading to discontinuation, deaths, electrocardiogram (ECG) abnormalities, and clinically significant laboratory abnormalities
To assess safety and tolerability as measured by incidence and severity of AEs
| Arm | Type | Description |
|---|---|---|
| Part 1, open label | EXPERIMENTAL | Inupadenant will be given at one or more dose levels to determine the recommended Phase 2 dose (RP2D). |
| Part 2, active treatment | EXPERIMENTAL | Treatment with inupadenant combined with carboplatin and pemetrexed |
| Part 2, placebo | PLACEBO_COMPARATOR | Treatment with matched placebo combined with carboplatin and pemetrexed |
| Inupadenant sequential dose escalation (Part 1A) | EXPERIMENTAL | Part 1A will evaluate the safety as well as to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of inupadenant in participants with advanced solid tumors. |
| Inupadenant randomized crossover (Part 1B) | EXPERIMENTAL | The effect of food on the exposure to inupadenant will be investigated in participants with advanced solid tumors. |
| Inupadenant single treatment assignment (Part 1C) | EXPERIMENTAL | Part 1C will investigate an additional formulation of inupadenant in participants with advanced solid tumors. |
| Name | Type | Description |
|---|---|---|
| inupadenant | DRUG | Adenosine 2a receptor antagonist |
| Placebo | DRUG | matched placebo capsule to inupadenant |
| Carboplatin | DRUG | standard of care chemotherapeutic, alkylating agent |
| Pemetrexed | DRUG | standard of care chemotherapeutic, anti-metabolite |
Inclusion Criteria: * Confirmed diagnosis of metastatic (Stage IV) or locally advanced, unresectable (Stage III) NSCLC of nonsquamous pathology * Measurable disease as defined by RECIST v1.1 * PD-L1 expression status available at or after the time of diagnosis. All levels of expression are eligible...
Inupadenant is an investigational small molecule being studied for the treatment of solid tumors and metastatic non-small cell lung cancer (NSCLC). It is being evaluated in adult patients with advanced cancers, including nonsquamous NSCLC, as part of ongoing clinical development programs.
Inupadenant is being developed by iTeos Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ITOS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in cancer patients.
Inupadenant is in clinical development, with studies in Phase 1 and Phase 2. A Phase 1 trial has been completed, and a Phase 2 trial is active but not recruiting patients. It is not yet approved by regulatory authorities and remains investigational.
Inupadenant has been studied in two clinical trials. NCT05117177 was a completed Phase 1 study of a new formulation in patients with solid tumors. NCT05403385 is an active Phase 2 study combining Inupadenant with chemotherapy as second-line treatment for nonsquamous non-small cell lung cancer.
Yes, Inupadenant is also known as EOS100850. Both names refer to the same investigational drug being developed by iTeos Therapeutics for the treatment of cancer, including solid tumors and non-small cell lung cancer.